Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Short Interest Update

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) was the recipient of a large drop in short interest during the month of February. As of February 28th, there was short interest totalling 12,600 shares, a drop of 40.0% from the February 13th total of 21,000 shares. Approximately 0.2% of the company’s shares are sold short. Based on an average daily volume of 81,300 shares, the days-to-cover ratio is currently 0.2 days.

Institutional Trading of Global X Genomics & Biotechnology ETF

Hedge funds and other institutional investors have recently modified their holdings of the business. Atria Investments Inc acquired a new stake in shares of Global X Genomics & Biotechnology ETF during the 3rd quarter worth about $122,000. Rockefeller Capital Management L.P. acquired a new position in Global X Genomics & Biotechnology ETF in the 3rd quarter valued at about $205,000. SBI Securities Co. Ltd. acquired a new position in Global X Genomics & Biotechnology ETF in the 4th quarter valued at about $50,000. Sanctuary Advisors LLC acquired a new position in Global X Genomics & Biotechnology ETF in the 4th quarter valued at about $104,000. Finally, Oxinas Partners Wealth Management LLC acquired a new position in Global X Genomics & Biotechnology ETF in the 4th quarter valued at about $103,000. 56.95% of the stock is owned by institutional investors and hedge funds.

Global X Genomics & Biotechnology ETF Price Performance

Shares of NASDAQ:GNOM traded up $0.10 during midday trading on Friday, reaching $8.84. 25,811 shares of the company’s stock were exchanged, compared to its average volume of 72,378. The firm’s 50 day simple moving average is $9.69 and its two-hundred day simple moving average is $10.31. The stock has a market cap of $61.61 million, a price-to-earnings ratio of -3.78 and a beta of 1.03. Global X Genomics & Biotechnology ETF has a fifty-two week low of $8.59 and a fifty-two week high of $11.88.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.